ResultsIQ

ResultsIQ › Latest results › Sumitomo Chemical India Limited

Sumitomo Chemical India Limited Q4 FY25 results deck summary

NSE: SUMICHEM · BSE: 542920

Results deck of 27 May 2025, summarised by AI from the filing.

FY25 revenue ₹3,148.5 cr (+11%), EBITDA ₹632.1 cr (+33%), PAT ₹506.4 cr (+37%); board approved new capex at Bhavnagar and Tarapur.

Key takeaways

  1. FY25 revenue FY25 revenue ₹3,148.5 cr (FY24: ₹2,843.9 cr, +11%)
  2. FY25 EBITDA FY25 EBITDA ₹632.1 cr (FY24: ₹474.6 cr, +33%)
  3. FY25 PAT FY25 net profit ₹506.4 cr (FY24: ₹369.7 cr, +37%)
  4. Risk Pricing pressure in multiple product categories adversely impacted revenue by approximately 10% in both domestic and export markets.

Original filing on BSE

Sumitomo Chemical India Limited Q1 FY27 results

As filed: Revenue ₹1,063 cr (+1% year on year), EBITDA ₹233 cr (+6% year on year), PAT ₹215 cr (+21% year on year), EBITDA margin 21.9% (+113 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹684 cr (+1% year on year), EBITDA ₹134 cr (+13% year on year), PAT ₹111 cr (+11% year on year), EBITDA margin 19.6% (+210 bps). Score 46 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 210 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −11.0% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹568 cr (−12% year on year), EBITDA ₹99.5 cr (−7% year on year), PAT ₹75.8 cr (+1% year on year), EBITDA margin 17.5% (+85 bps). Score 25 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 85 bps year on year. Other income 36% of PBT. Revenue fell 39% from last quarter. Share price after the results: −5.1% in 30 days (Nifty 500: +3.3%).
  • Q2 FY26: Revenue ₹930 cr (−6% year on year), EBITDA ₹218 cr (−11% year on year), PAT ₹178 cr (−8% year on year), EBITDA margin 23.4% (−146 bps). Score 30 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 146 bps year on year. Revenue fell 12% from last quarter. Share price after the results: −11.9% in 30 days (Nifty 500: +1.1%).
  • Q1 FY26: Revenue ₹1,057 cr (+26% year on year), EBITDA ₹220 cr (+37% year on year), PAT ₹178 cr (+40% year on year), EBITDA margin 20.8% (+162 bps). Score 75 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 162 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹218 cr on a year ago, more than the ₹115 cr it added the year before. Share price after the results: −6.4% in 30 days (Nifty 500: +0.8%).
  • Q4 FY25: Revenue ₹679 cr (+1% year on year), EBITDA ₹119 cr (−15% year on year), PAT ₹100 cr (−9% year on year), EBITDA margin 17.5% (−325 bps). Score 32 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA growth was well below it; profit growth was below it. EBITDA margin fell 325 bps year on year. Share price after the results: −4.2% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹642 cr (+18% year on year), EBITDA ₹107 cr (+65% year on year), PAT ₹87.0 cr (+58% year on year), EBITDA margin 16.7% (+467 bps). Score 54 of 100, In line with trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 467 bps year on year. Other income 26% of PBT. Revenue fell 35% from last quarter.
  • Q2 FY25: Revenue ₹988 cr (+9% year on year), EBITDA ₹246 cr (+32% year on year), PAT ₹193 cr (+35% year on year), EBITDA margin 24.9% (+419 bps). Score 70 of 100, Above trend. EBITDA margin rose 419 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Sumitomo Chemical India Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.